Building a Better Diagnosis System for Thyroid Eye Disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study aims to build a better system for diagnosing and treating thyroid-associated ophthalmopathy (a thyroid eye condition). It may help improve care for people with this disease, and also involves healthy volunteers as a comparison group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must either have thyroid-associated ophthalmopathy (thyroid eye disease) or be a healthy person without eyelid problems.
- You need to be able to cooperate with the study procedures.
- You cannot have any current problem with your pupil or cornea (the clear front part of your eye).
- You cannot have a history of an eye injury.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
This study looks at how doxycycline (an antibiotic) affects thyroid eye disease using special imaging pictures. It may help doctors better understand disease activity and how well treatments work.
This study uses eye tracking to compare how people with thyroid eye disease move their eyes and pay attention to visual cues. It may help researchers understand eye movement problems better.
This study uses MRI scans of the eye area to better understand and classify thyroid eye disease (TED). It aims to help doctors predict outcomes and personalize treatment. You may be eligible if you have stable TED or are a healthy volunteer.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.